Pituitary tumor‑transforming 1 expression in laryngeal cancer and its association with prognosis

Ma, Ke; Ma, Limin; Zhao-cheng, Jian

doi:10.3892/ol.2018.8745

Cited by 3 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of stained cells was calculated as: 0, <5% stained; 1+, 5% to 25% stained; 2+, 26% to 50% stained; 3+, 51% to 75% stained; 4+, 76% to 100% stained. As shown in previously published studies, the product of the two staining variable scores represented the Tra2β score for each sample. A score of ≥6 was considered high expression, whereas a score < 6 was considered low expression.…”

Section: Methodsmentioning

confidence: 96%

“…Accordingly, the present findings suggested that abnormal expression of Tra2β is associated with LSCC progression, and Tra2β may play an important role in diagnosis and served as a potential biomarker, as other studies previously reported. [13][14][15][16][17][18][19][20][21][22][23][24][25]…”

Section: Tra2β Is Upregulated In Lscc Tissues and Significantly Assocmentioning

confidence: 99%

See 1 more Smart Citation

Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/AKT signaling

Chen

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

Objectives/Hypothesis Transformer‐2 protein homolog beta (Tra2β) generally plays an important role in various human cancers, but its role and the underlying mechanisms in laryngeal squamous cell carcinoma (LSCC) remained unknown. So this study aimed to assess the clinical significance and regulatory mechanisms of Tra2β in LSCC. Study Design Laboratory analysis. Methods Expression of Tra2β was compared in human LSCC tissue samples and paired adjacent normal tissue samples. The in vitro effects of Tra2β expression in Hep‐2 cells on their proliferation, invasion, and migration were assessed by CCK‐8 assays, Matrigel invasion, and transwell migration assays. In addition, the effects of downregulation of Tra2β on the activation of PI3K/AKT signaling pathway were measured using Western blot analysis. The effect of Tra2β on the growth of tumors was detected in the Hep‐2–injected xenograft models in vivo. Results Reverse‐transcription quantitative polymerase chain reaction analysis and immunochemistry analysis indicated that the increased expression of Tra2β in LSCC was significantly associated with poor differentiation, lymph node metastasis, and advanced clinical stage. In vitro knockdown of Tra2β caused a significant decrease in the proliferation, invasion, and migration of Hep‐2 cells. Tra2β silencing decreased the expression of Bcl‐2 but increased Bax and Caspase‐3 both in mRNA and protein levels. Furthermore, knockdown of Tra2β eliminated the suppressive effects of activation of PI3K/AKT signaling. In vivo knockdown of Tra2β significantly inhibited the tumor growth of Hep‐2–injected xenograft mice. Conclusions The results of the present study demonstrated that knockdown of Tra2β inhibits the proliferation and invasion of LSCC cells, at least partly via inhibiting PI3K/AKT signaling. Level of Evidence NA Laryngoscope, 129:E318–E328, 2019

show abstract

Section: Methodsmentioning

confidence: 96%

Section: Tra2β Is Upregulated In Lscc Tissues and Significantly Assocmentioning

confidence: 99%

Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/AKT signaling

Chen

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…At last, A total of 25 articles with 26 studies were selected for this meta-analysis. [2,9,[17][18][19][21][22][23][25][26][27][28][38][39][40][41][42][43][44][45][46][47][48][49][50] A flowchart of the study search and selection process is depicted in Figure 1.…”

Section: Literature Search and Selectionmentioning

confidence: 99%

“…Nevertheless, these studies have yielded conflicting results regarding the prognostic significance of securin in human cancers. Most studies indicate that high securin expression is closely correlated with poorer overall survival (OS) and even acts as an independent prognostic biomarker in patients with malignant tumors, such as esophageal cancer, [ 2 ] HCC, [ 17 , 18 ] endometrial cancer, [ 19 , 20 ] glioma, [ 21 ] gastric cancer, [ 22 ] laryngeal cancer, [ 23 , 24 ] lung cancer, [ 9 , 25 ] colorectal cancer, [ 26 ] renal cell cancer, [ 27 ] osteosarcoma, and bladder cancer. [ 28 ] Conversely, one individual study has shown that the securin expression level is not related to survival outcome in cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of securin expression in solid cancers: A PRISMA-compliant meta-analysis of published studies and bioinformatics analysis based on TCGA dataset

Liu¹,

Zeng²,

Zheng³

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Numerous studies have investigated the clinical significance of securin expression in solid cancers; however, the results have been inconsistent. Hence, we performed a meta-analysis of published studies to assess the clinical value of securin expression in patients with solid cancers. Methods: The Chinese National Knowledge Infrastructure, Web of Science, PubMed, and EMDASE databases were searched for eligible studies (from inception up to April 2021). Bioinformatics analysis based on The Cancer Genome Atlas dataset was also performed to evaluate the prognostic value of securin expression. Results: A total of 25 articles with 26 studies were included in the meta-analysis. The results of the meta-analysis implied that high securin expression was positively correlated with unfavorable overall survival (OS) (hazard ratio = 1.52, 95% CI, 1.33–1.73; P < .001) and lymph node metastasis (odd ratio = 2.96, 95% CI, 2.26–3.86; P < .001). Consistently, our bioinformatics analysis showed that increased securin expression was associated with worse OS and shorter disease-free survival in cancer patients. Conclusion: Our study indicated that securin overexpression was positively associated with metastasis and inversely related to the prognosis of patients with solid cancers. However, additional high-quality studies should be conducted to validate these findings.

show abstract

Novel Signaling Pathway and NSC689534 as a Potential Drug Candidate for Cutaneous Squamous Cell Carcinoma

Miao,

Shen,

Zhang

et al. 2024

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy of the skin, and its incidence is increasing annually. Once cSCC becomes metastatic, its associated mortality rate is much higher than that of cSCC in situ. However, the current treatments for progressive cSCC have several limitations. The aim of this study was to suggest a potential compound for future research that may benefit patients with cSCC. Methods: In this study, we screened the following differentially expressed genes from the Gene Expression Omnibus database: GSE42677, GSE45164, GSE66359, and GSE98767. Using strategies such as protein-protein interaction network analysis and the CYTOSCAPE plugin MCODE, key modules were identified and then verified by Western blotting. Subsequently, related signalling pathways were constituted in the SIGNOR database. Finally, molecular docking analyses and cell viability assay were used to identify a potential candidate drug and verify its growth inhibition ability to A431 cell line. Results: Fifty-one common differentially expressed genes were screened and two key modules were identified. Among them, three core genes were extracted, constituting two signalling pathways, both of which belong to the module associated with mitotic spindles and cell division. A pathway involving CDK1, the TPX2-KIF11 complex, and spindle organization was validated in a series of analyses, including analyses for overall survival, genetic alteration, and molecular structure. Molecular docking analyses identified the pyridine 2-carbaldehyde thiosemicarbazone (NSC689534), which interacts with TPX2 and KIF11, as a potential candidate for the treatment of cSCC. Conclusions: NSC689534 might be a candidate drug for cSCC targeting TPX2 and KIF11, which are hub genes in cSCC.

show abstract

Pituitary tumor‑transforming 1 expression in laryngeal cancer and its association with prognosis

Cited by 3 publications

References 35 publications

Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/AKT signaling

Tra2β silencing suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting PI3K/AKT signaling

Clinical significance of securin expression in solid cancers: A PRISMA-compliant meta-analysis of published studies and bioinformatics analysis based on TCGA dataset

Novel Signaling Pathway and NSC689534 as a Potential Drug Candidate for Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About